Telehealth stocks like Hims & Teladoc are expected to gain from new FDA pick.

From Investing.com: 2024-12-06 10:35:00

The Trump administration nominated Dr. Marty Makary for FDA commissioner, boosting telehealth stocks like Hims & Hers Health with 77.1% YoY revenue growth. Eli Lilly requested FDA to remove Tirzepatide from the shortage list, benefiting Hims. Dr. Makary advocates for FDA transparency and telemedicine, fueling an 18% stock rally for HIMS. Teladoc, the largest telehealth platform, is making a turnaround post-pandemic with revenue guidance raised to $646-662 million. Goldman Sachs initiated coverage of Teladoc with a buy rating and $14 price target, expecting membership growth and BetterHelp expansion in 2026.



Read more at Investing.com: 2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick